MET · METLIFE INC

795 filings

MET SEC Filings

METLIFE INC - 795 total filings

Filing record · 2016–202610-K1110-Q328-K249

Showing 1–50 of 795 filings

METLIFE INC 8-K Report, Regulation FD Disclosure (Sep 24, 2026)

MetLife, Inc. has issued an 8-K filing to provide preliminary insights into its variable investment income for the third quarter of 2026, ahead of its official earnings release. The company estimates this income to be at least $600 million (pre-tax). This figure provides investors with an early indication of performance in key alternative investment areas, including private equity, real estate, and prepayment fees. While this disclosure offers a glimpse into a specific component of MetLife's revenue, it's crucial for investors to understand that these are preliminary, unaudited results. The company explicitly cautions that actual results may differ materially from these estimates. Investors should exercise caution and not rely solely on this information, as it is not a substitute for the full financial statements prepared under U.S. GAAP, which will be released on November 4, 2026.

Sep 24, 2026 8-K

METLIFE INC 8-K Report, Corporate Update (Aug 17, 2026)

MetLife, Inc. (NYSE: MET) announced on August 17, 2026 that it has declared its third quarter 2026 preferred stock dividends across four series, as disclosed under Item 8.01 of this Form 8-K with the news release attached as Exhibit 99.1. The declarations cover the floating rate non-cumulative Series A (quarterly, $0.31471411 per share), the 5.875% fixed-to-floating Series D (semi-annual, $29.375 per share on $1,000 liquidation preference), the 5.625% Series E (quarterly, $0.3515625 per depositary share), and the 4.75% Series F (quarterly, $0.296875 per depositary share). All dividends are payable September 15, 2026, to holders of record as of August 31, 2026. This is a routine capital-management disclosure rather than a material operational or financial event. The filing contains no earnings data, guidance changes, balance sheet updates, or new capital actions such as issuances or repurchases. The dividends are non-cumulative, meaning MetLife has no obligation to pay missed amounts, so each declaration is a discretionary board decision that signals ongoing confidence in the company's capital position. For investors, the main takeaway is that MetLife continues to service its preferred capital stack on schedule, which supports the credit profile of these instruments and reflects the company's ongoing use of hybrid capital. Investors in the preferred securities should note the payment dates and record dates, while common shareholders will find little new information here beyond confirmation of the ongoing preferred capital structure.

Aug 17, 2026 10-Q

METLIFE INC Quarterly Report for Q2 Ended Jun 30, 2026

MetLife, Inc. reported solid financial results for the six months ended June 30, 2026. Net income available to common shareholders increased to $1.845 billion from $1.674 billion in the same period last year, driven by a significant rise in adjusted earnings, which grew to $3.159 billion from $2.711 billion. The company's strategic reorganization, completed in late 2025, appears to be yielding positive results, with the newly formed MetLife Investment Management (MIM) segment contributing to growth, boosted by the acquisition of PineBridge Investments. Despite a challenging macroeconomic environment marked by interest rate volatility and inflation, MetLife demonstrated resilience across its various segments, including Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, and EMEA. The company's investment portfolio remains a key driver of its performance, with net investment income showing a robust increase. MetLife's strong capital management and liquidity position were maintained, evidenced by substantial cash and invested assets, and the company continued its commitment to shareholder returns through common stock repurchases and preferred dividends. The company's outlook remains cautiously optimistic, with ongoing efforts to navigate market complexities and capitalize on growth opportunities.

Aug 6, 2026 8-K

METLIFE INC 8-K Report, Financial Results (Aug 5, 2026)

MetLife reported second-quarter 2026 adjusted earnings of $1.573 billion, up 15% year over year, or $2.43 per diluted share, up 20%. Growth was driven by favorable underwriting and broad volume growth across segments. Group Benefits (+25%), Asia (+21%), and Latin America (+15%) led. Adjusted ROE was 17.0%, at the top of management's 15-17% target range. Reported GAAP net income rose only 1% to $705 million ($1.09 per share, up 6%). The gap reflects $428 million of pre-tax net investment losses and $772 million of pre-tax net derivative losses, which are excluded from adjusted earnings. Investors should therefore weigh the adjusted figures against the more volatile GAAP results. Top-line growth was solid. Premiums, fees and other revenues rose 7% to $13.7 billion, and adjusted PFOs excluding pension risk transfers (PRT) rose 5% to $13.0 billion. Net investment income rose 18% to $6.7 billion, but adjusted net investment income grew a more modest 7% to $5.6 billion. Variable investment income was $231 million, below the company's approximately $400 million quarterly target, reflecting lower private equity returns. The direct expense ratio was 12.1% excluding PRT and notable items, slightly above the prior-year 11.7% but on track to beat the full-year target. The reported expense ratio rose to 21.7% from 19.8%. Capital return was significant. MetLife returned over $1.1 billion to shareholders in the quarter through about $700 million of buybacks and about $400 million of dividends, and announced a new $3.0 billion repurchase authorization. Diluted share count fell to 646.9 million from 675.0 million, and book value per share rose 8% to $38.59. Adjusted book value per share rose only 3% to $57.71. Holding company cash and liquid assets were $3.4 billion, within the company's target range.

Aug 5, 2026 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Jun 29, 2026)

MetLife, Inc. (MET) has filed a Form 8-K to provide investors with preliminary insights into its variable investment income for the quarter ending June 30, 2026. The company estimates this income to be in the range of $220 million to $270 million (pre-tax). This preliminary figure offers a mid-quarter update ahead of the official earnings release scheduled for August 5, 2026, which will include the full quarterly financial supplement. This disclosure is important for investors tracking MetLife's diversified income streams, particularly those derived from private equity, real estate, and other funds, as well as prepayment fees. While this information is preliminary and unaudited, it provides a directional indication compared to the company's full-year 2026 guidance of approximately $1.6 billion (pre-tax) for variable investment income. Investors should exercise caution as actual results may differ materially, and this data should not replace the comprehensive financial statements.

Jun 29, 2026 8-K

METLIFE INC 8-K Report, Shareholder Vote Results (Jun 22, 2026)

MetLife, Inc. (MET) reported the results of its annual meeting of common shareholders held on June 16, 2026. The filing indicates strong shareholder support for the company's governance and executive compensation practices. All eleven director nominees were elected, and the appointment of Deloitte & Touche LLP as the independent auditor for 2026 was ratified with a substantial majority of votes. Additionally, shareholders provided advisory approval for the compensation of Named Executive Officers, signaling confidence in the company's leadership and compensation structure. These results suggest a stable shareholder base that is largely aligned with the current board and management. The overwhelming support for director elections and auditor ratification underscores a healthy corporate governance framework. Investors can view these outcomes as positive indicators of continuity and trust in MetLife's operational and strategic direction.

Jun 22, 2026 8-K

METLIFE INC 8-K Report, Corporate Update (May 15, 2026)

MetLife, Inc. (NYSE: MET) filed a Form 8-K on May 15, 2026, under Item 8.01 (Other Events) to announce the declaration of quarterly dividends on three series of its preferred stock for the second quarter of 2026. The filing is routine in nature: it covers the floating rate non-cumulative Series A preferred (MET PRA), the 5.625% non-cumulative Series E preferred (MET PRE), and the 4.75% non-cumulative Series F preferred (MET PRF). No financial results, guidance, leadership changes, or material transactions are disclosed in the filing itself. The dividends are payable June 15, 2026, to holders of record as of May 29, 2026. Because the scheduled record date of May 31, 2026 falls on a Sunday, the record date is set to the preceding Friday, May 29. Per-share amounts are $0.31190376 for Series A, $0.3515625 per depositary share for Series E, and $0.296875 per depositary share for Series F. Each depositary share represents a 1/1,000th interest in a share of the underlying preferred stock with a $25,000 liquidation preference. For investors, the key takeaway is that MetLife continues to meet its scheduled preferred dividend obligations. Because these preferred securities are non-cumulative, a skipped dividend would not accumulate and be owed later, so the declaration itself confirms current payment capacity and board support for the capital structure. Investors holding these securities should note the May 29 record date for eligibility, and the filing offers no direct read-through to the common stock outlook.

May 15, 2026 10-Q

METLIFE INC Quarterly Report for Q1 Ended Mar 31, 2026

MetLife, Inc. reported solid financial results for the first quarter of 2026. The company's net income available to common shareholders increased to $1.14 billion, a significant improvement from $879 million in the prior year's quarter. This growth was primarily driven by a favorable shift in net investment gains and a strong recovery in net derivative gains. The company also saw a significant boost in adjusted earnings available to common shareholders, reaching $1.59 billion, up from $1.35 billion year-over-year, reflecting operational improvements and strategic execution. Total assets stood at $743.2 billion as of March 31, 2026, with total liabilities at $715.4 billion. The balance sheet remains robust, supported by substantial investment portfolios, primarily in fixed maturity securities. The company's strategic reorganization, completed in late 2025, has realigned its segments to focus on growth, particularly within its asset management business (MIM). Key segments like Group Benefits and Retirement & Income Solutions (RIS) demonstrated strong adjusted earnings growth, contributing significantly to the overall positive performance. The company continues to manage its capital effectively, returning value to shareholders through share repurchases and dividends.

May 7, 2026 8-K

METLIFE INC 8-K Report, Financial Results (May 6, 2026)

MetLife (MET) reported strong first-quarter 2026 results, with adjusted earnings per share up 23% to $2.42 and net income up 30% to $1.1 billion, or $1.74 per share. Adjusted earnings rose 18% to $1.6 billion, driven by higher variable investment income (up 58% to $518 million on private equity returns), volume growth, and favorable life underwriting. Premiums, fees and other revenues grew 5% to $14.3 billion, and adjusted PFOs excluding pension risk transfers (PRT) rose 10% to $13.3 billion, with growth in every segment. Adjusted ROE was 17.0% and GAAP ROE 18.2%, and book value per share rose 8% to $37.92 while adjusted book value per share rose 4% to $57.41. Capital deployment remained active: MetLife returned over $1.1 billion to shareholders in the quarter through about $750 million of buybacks and roughly $370 million of common dividends, with a further roughly $200 million of repurchases in April 2026. Holding company cash and liquid assets ended the quarter at $3.9 billion, at the top of the target range. The 2025 combined NAIC RBC ratio was 379%, above the 360% target, while U.S. statutory adjusted capital fell about 5% to an expected $16.2 billion. Management said the results reflect progress in year two of the New Frontier plan, and the company reported a direct expense ratio of 11.9% against a 12.1% full-year target. Investors should note several watch items. Quality of earnings is supported by private equity returns, which are inherently volatile, and variable investment income of $518 million is tracking toward the ~$1.6 billion full-year 2026 guidance. Net investment losses of $670 million and a $120 million market risk benefit remeasurement loss weighed on GAAP net income, and Latin America adjusted earnings fell 9% on a constant currency basis due to the Mexico value-added tax change. The filing states that the earnings release and financial supplement are furnished rather than filed, and it includes a standard forward-looking statements disclaimer.

May 6, 2026 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Apr 7, 2026)

MetLife, Inc. (MET) has filed a Form 8-K to provide preliminary guidance on its variable investment income for the first quarter of 2026. The company estimates this income, which includes returns from private equity, real estate, and other funds, as well as prepayment fees, to be between $475 million and $525 million on a pre-tax basis. This figure is part of the company's previously issued full-year 2026 guidance of approximately $1.6 billion in variable investment income. While this provides early insight into a key component of MetLife's investment performance, investors are cautioned that these numbers are preliminary, unaudited, and based on information available as of the filing date. Actual results could differ materially once full financial closing procedures are completed. The company emphasizes that this disclosure should not be seen as a substitute for their full U.S. GAAP financial statements and that no inferences should be drawn about other financial or operating data not provided here.

Apr 7, 2026 8-K

METLIFE INC 8-K Report, Corporate Update (Mar 5, 2026)

MetLife, Inc. (NYSE: MET) issued a news release on March 5, 2026, confirming its previously announced declaration of a first quarter 2026 dividend of $0.31501229 per share on its floating rate non-cumulative preferred stock, Series A (NYSE: MET PRA), which carries a $25 per share liquidation preference. This filing is a routine confirmatory disclosure under Item 8.01 (Other Events) and does not contain new financial results, guidance, or strategic announcements. The dividend is payable March 16, 2026, to holders of record as of Friday, February 27, 2026, because the nominal record date of Sunday, March 1, 2026 fell on a non-business day. The NYSE has not yet set an ex-dividend date for the preferred shares and will do so following this confirmation. Investors holding the preferred should note that the record-date timing means the ex-dividend date will likely align with the record date, so purchases on or after that date may not entitle buyers to the payment. For equity and fixed-income investors, the filing is primarily informational. The per-share amount reflects a floating rate structure, so the payout will adjust periodically with the reference rate specified in the preferred stock terms. The filing contains no changes to MetLife's common dividend, capital position, or operating outlook.

Mar 5, 2026 8-K

METLIFE INC 8-K Report, Financial Obligation (Feb 26, 2026)

MetLife Inc. has announced the issuance of $1 billion in 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056. This debt issuance, finalized on February 26, 2026, was conducted under the company's existing shelf registration statement and a recently filed prospectus supplement. The funds raised are expected to support MetLife's ongoing business operations and strategic initiatives. From an investor's perspective, this subordinated debt issuance represents a new layer of leverage for MetLife. While offering a fixed coupon rate initially, the 'Fixed-to-Fixed Reset Rate' feature implies potential adjustments to the interest rate over the life of the debentures. Investors should note the subordinated nature of these debentures, meaning they rank below senior debt in the event of liquidation. The details of the underwriting and pricing agreements with major financial institutions indicate a well-structured offering.

Feb 26, 2026 8-K

METLIFE INC 8-K Report, Executive Changes (Feb 24, 2026)

MetLife, Inc. (MET) announced a significant change to its Board of Directors on February 24, 2026, by increasing the board size from eleven to thirteen members and appointing two new independent directors, Daniel S. Glaser and Michelle R. Seitz. Both directors have been immediately assigned to key board committees, reflecting their expertise and the company's strategic focus on governance, risk, compensation, and investment oversight. This expansion and appointment of experienced individuals are intended to enhance the board's capabilities and provide diverse perspectives crucial for navigating the complex financial services landscape.

Feb 24, 2026 10-K

METLIFE INC Annual Report, Year Ended Dec 31, 2025

MetLife's 2025 Form 10-K shows a company in the midst of a strategic pivot toward asset management and group benefits, with steady adjusted earnings but compressed GAAP net income. Net income available to common shareholders fell to $3.2 billion in 2025 from $4.2 billion in 2024, driven primarily by unfavorable market risk benefit remeasurement and derivative results, while adjusted earnings available to common shareholders rose 2.5% to $5.9 billion. Management's key operating metrics point to resilience: adjusted premiums, fees and other revenues grew 10% to $57.4 billion, led by pension risk transfer and U.K. longevity reinsurance growth in RIS, and Asia and Latin America contributed strongly to segment earnings. The filing also marks a structural change. Under the New Frontier strategy, MetLife reorganized into six segments, adding MetLife Investment Management as a reportable segment and folding MetLife Holdings into Corporate & Other, and it closed the roughly $885 million cash acquisition of PineBridge Investments on December 30, 2025. Capital return remained substantial, with about $4.4 billion returned to shareholders in 2025, a $2.1 billion repurchase authorization remaining, and free cash flow of $4.9 billion across all holding companies, equal to 82% of adjusted earnings. Management maintained its 2026 targets of 15%-17% adjusted ROE, double-digit adjusted EPS growth, and a $25 billion five-year free cash flow goal for 2025-2029. Risks investors should weigh include a 2025 effective tax rate of 27% (versus 21% in 2024), a $100 million Mexican value-added tax charge, the forthcoming VM-22 principle-based reserving requirement for non-variable annuities, sensitivity of earnings to interest rate scenarios, a $2.2 billion increase in long-term debt and subordinated debt, and a large and growing asbestos liability. Net investment income rose to $22.6 billion, and the company's insurer financial strength ratings remained in the AA- to A+ range across major agencies.

Feb 19, 2026 8-K

METLIFE INC 8-K Report, Corporate Update (Feb 17, 2026)

MetLife, Inc. (NYSE: MET) filed an 8-K on February 17, 2026 under Item 8.01 (Other Events) to announce its first quarter 2026 preferred stock dividend actions. The filing is routine in nature: the company declared dividends on four series of non-cumulative preferred stock, including a semi-annual dividend on Series D (5.875% fixed-to-floating rate), quarterly dividends on Series E (5.625%) and Series F (4.75%), and a quarterly dividend on its floating rate Series A. No financial results, guidance, strategic transactions, or leadership changes are disclosed in the filing. The declared dividends are payable March 16, 2026, to holders of record as of February 27, 2026. The Series A dividend of $0.31501229 per share is conditional: it is subject to MetLife confirming it has met the financial tests in the Series A certificate of designations, which the company expects to announce on or about March 5, 2026. The NYSE has not yet set an ex-dividend date for Series A and will do so only after that confirmation. Investors in the Series A preferred should watch for this confirmation before relying on the payment. For investors, the main significance is the continued payment of preferred dividends, which signals that MetLife is meeting its obligations to preferred holders and is maintaining its capital distributions. Because these are non-cumulative instruments, missed dividends would not accrue, so the conditional Series A payment is the one item that warrants monitoring. The filing does not provide information on earnings, capital ratios, or the company's broader financial condition.

Feb 17, 2026 8-K

METLIFE INC 8-K Report, Financial Results (Feb 4, 2026)

MetLife's 4Q25 and full-year 2025 results were solid, with the company beating its direct expense ratio and free cash flow targets and delivering roughly 10% adjusted EPS growth, although GAAP results were weaker. Full-year net income was $3.2 billion, or $4.71 per share, down 25% from 2024, while adjusted earnings per share excluding total notable items rose 10% to $8.89. Adjusted ROE excluding notable items was 16.0%, at the midpoint of the company's 15%-17% target. Fourth-quarter net income fell 37% to $778 million, driven by net derivative losses and net investment losses, while adjusted earnings rose 13% to $1.6 billion and adjusted EPS excluding notables increased 24% to $2.58. Top-line growth was driven largely by the risk and insurance solutions (RIS) business, where record pension risk transfer (PRT) sales and U.K. longevity reinsurance boosted premiums. Fourth-quarter premiums, fees and other revenues rose 29% to $18.7 billion, but adjusted PFOs excluding PRT grew a more modest 8%. Variable investment income of $497 million in the quarter, mainly from private equity returns, also lifted results. Asset management also expanded materially after the PineBridge Investments acquisition closed on December 30, 2025, lifting MetLife Investment Management AUM to $741.7 billion. Capital and outlook remain central to the investment case. Holding company cash and liquid assets were $3.6 billion, within the $3.0-$4.0 billion target, and the company returned about $4.4 billion to shareholders in 2025. Management reaffirmed its 2026 targets, including a 12.1% direct expense ratio, double-digit adjusted EPS growth, a 65%-75% free cash flow ratio, and approximately $25.0 billion of free cash flow over 2025-2029. The 2026 variable investment income guidance of about $1.6 billion pre-tax assumes a 9% private equity return. Investors will likely focus on whether earnings quality holds up given the reliance on volatile variable investment income and on the pace of PRT and PineBridge integration.

Feb 4, 2026 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Jan 9, 2026)

MetLife (MET) filed an 8-K on January 9, 2026 under Item 7.01 (Regulation FD) to furnish a Historical Results Financial Supplement (Exhibit 99.1) that recasts prior-period results to reflect a fourth-quarter 2025 reorganization. The company now reports six segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, EMEA, and MetLife Investment Management (MIM). MIM, previously in Corporate & Other, is now a reportable segment, while MetLife Holdings is no longer a segment and has been folded primarily into Corporate & Other, with some products moved into Group Benefits and RIS. The company also changed agreements so MIM manages general account assets at current market fee rates effective January 1, 2025. Management states none of these changes affect prior-period consolidated net income or adjusted earnings, so this filing is primarily a presentation change rather than a change in reported performance. The recast supplement gives investors a restated baseline for 2024 and the first three quarters of 2025. Consolidated figures in the exhibit show total revenues of $70.99 billion and net income attributable to MetLife of $4.43 billion for 2024. Quarterly adjusted earnings available to common shareholders were $1,459 million in Q4 2024, $1,349 million in Q1 2025, $1,362 million in Q2 2025, and $1,584 million in Q3 2025. Q3 2025 included $18 million of net notable items, and adjusted book value per share rose from $54.81 at year-end 2024 to $56.57 at September 30, 2025. Book value per share rose more sharply, from $34.28 to $39.52, reflecting recovery in unrealized investment losses. For investors, the key takeaways are the improved transparency of the new segment structure, particularly the separate visibility of MIM as an asset manager, and the restated quarterly comparisons needed to evaluate segment trends. Because the filing is furnished rather than filed and does not itself contain new guidance or a change in earnings, its main value is as a tool for modeling 2025 and 2026 results on the new basis. Investors should note that the exhibit covers only historical periods; the full-year 2025 results under the new format are to come in the subsequent Quarterly Financial Supplement.

Jan 9, 2026 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Dec 30, 2025)

On December 30, 2025, MetLife, Inc. announced that MetLife Investment Management (MIM), its institutional asset management arm, closed its acquisition of PineBridge Investments, LLC and certain affiliates. The combined business reports pro forma total assets under management of $734.7 billion as of September 30, 2025, comprising $632.6 billion from MIM and $102.1 billion from PineBridge. The company frames the deal as a key step in its New Frontier strategy, which prioritizes growth in asset management, and positions MIM as a top-tier diversified global asset manager. The pro forma institutional client AUM totals $314.6 billion, with insurance clients representing the largest share at $115.4 billion, followed by pension at $93.8 billion and intermediary (including sub-advisory) at $65.3 billion. Insurance AUM of $535.6 billion is a significant component of total AUM, reflecting MetLife's general account and separate account assets. More than half of the PineBridge client assets are held by non-U.S. investors, with roughly one-third in Asia, which broadens MIM's geographic footprint. Brian Funk, president of MIM, will lead the combined business post-close, and the release notes the acquisition excludes PineBridge's private equity funds group and its China joint venture. Investors should note that the $734.7 billion figure is explicitly illustrative, presented as if the deal had closed on September 30, 2025, and does not reflect actual combined results for any completed period. The filing contains no disclosure of purchase price, financing terms, or expected earnings contribution, so the financial impact on MetLife's earnings and capital position cannot be assessed from this document alone. The forward-looking statements caution that future results could differ materially from expectations.

Dec 30, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Dec 22, 2025)

MetLife, Inc. has filed an 8-K report to provide investors with a preliminary update on its financial performance and outlook for the fiscal year ending December 31, 2025, ahead of its official earnings release. The company anticipates variable investment income for the fourth quarter of 2025 to be between $385 million and $435 million (pre-tax), slightly below its quarterly target of $425 million, but expects its full-year 2025 variable investment income to be around $1.7 billion (pre-tax). In terms of capital management, MetLife is prioritizing organic growth, with an estimated $4 billion deployed in 2025, and an additional $1 billion for M&A, including the pending acquisition of PineBridge Investments. The company also expects to repurchase approximately $2.85 billion of its common stock in 2025, a level it anticipates maintaining in 2026. Investors should note that this information is preliminary and unaudited, and actual results could materially differ.

Dec 22, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Dec 1, 2025)

MetLife, Inc. (NYSE: MET) reported in an 8-K dated December 1, 2025 that it has completed its previously announced transaction with Talcott Resolution Life Insurance Company to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves. The transaction is part of MetLife's ongoing risk-transfer program within MetLife Holdings, the closed-block businesses of its former U.S. Retail segment, and is intended to reduce portfolio risk and accelerate the run-off of legacy blocks. The key economic trade-off disclosed is an expected foregone annual adjusted earnings impact of approximately $100 million, partially offset by approximately $45 million in annual hedge cost savings, implying a net reduction of roughly $55 million in annual adjusted earnings before any other effects. Investors should weigh this against the benefit of lower market and hedging risk on the variable annuity book, which has historically been a source of earnings volatility for life insurers. As an additional element, MetLife Investment Management will manage approximately $6 billion of assets under investment management agreements with Talcott, a modest fee-generating mandate. The news release is furnished under Item 7.01 rather than filed, so it is not subject to the liability provisions of Section 18 of the Exchange Act.

Dec 1, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (Nov 17, 2025)

MetLife, Inc. (NYSE: MET) filed a routine Form 8-K on November 17, 2025 under Item 8.01 (Other Events) to announce its fourth quarter 2025 preferred stock dividend declarations across three series: the floating rate non-cumulative Series A (MET PRA), the 5.625% non-cumulative Series E (MET PRE), and the 4.75% non-cumulative Series F (MET PRF). The filing contains no new financial results, guidance, or material operational developments, and the dividends are payable December 15, 2025 to holders of record as of November 28, 2025. For investors, the key takeaway is that MetLife is maintaining its preferred dividend obligations on schedule, which signals continued capital management discipline and confidence in its liquidity position. Because these preferred shares are non-cumulative, a missed dividend would not accrue as arrears, so consistent declarations are a meaningful, though incremental, indicator of financial health rather than a catalyst for the common stock. The per-share amounts are standard for these issues: Series A pays approximately $0.335 per $25 share, while Series E and F pay $0.3515625 and $0.296875 per depositary share respectively, each representing a 1/1,000th interest in a $25,000 preferred share. Overall, the filing is a routine administrative disclosure with limited immediate market impact, and investors should focus on MetLife's quarterly earnings and capital metrics for a fuller picture.

Nov 17, 2025 10-Q

METLIFE INC Quarterly Report for Q3 Ended Sep 30, 2025

MetLife Inc. reported its third-quarter 2025 financial results, showing a decrease in net income available to common shareholders to $818 million, or $1.22 per diluted share, compared to $1.3 billion, or $1.81 per diluted share, in the same period of 2024. This decline was primarily attributed to unfavorable changes in net investment gains/losses and significant unfavorable changes in net derivative gains/losses, largely due to currency movements and interest rate fluctuations. Despite the decline in net income, adjusted earnings available to common shareholders remained relatively stable at $1.6 billion for the three months ended September 30, 2025, compared to $1.4 billion in the prior year's quarter. This resilience in adjusted earnings was driven by positive market factors such as higher private equity returns and recurring investment income, as well as volume growth across segments like Asia and Latin America. However, underwriting adjustments and expense management were areas that presented challenges. The company's total assets grew to $719.7 billion, with a continued focus on managing its investment portfolio and capital resources.

Nov 7, 2025 8-K

METLIFE INC 8-K Report, Financial Results (Nov 5, 2025)

MetLife (MET) reported third-quarter 2025 results on November 5, 2025, with net income available to common shareholders of $818 million, or $1.22 per diluted share, down 33% from $1.81 a year earlier. The decline was driven mainly by a $929 million net derivative loss (versus a $767 million gain in 3Q24) and $325 million of net investment losses, partially offset by a $263 million market risk benefit remeasurement gain. Management's preferred performance gauge, adjusted earnings, rose 15% to $1.6 billion ($2.37 per share, up 22%), and excluding total notable items, adjusted EPS grew 21% to $2.34. Growth was led by higher variable investment income of $483 million, which came in well above the company's quarterly target, largely from private equity returns, and by strong Asia results. Top-line growth was modest. Premiums, fees and other revenues were flat at $12.5 billion, while adjusted PFOs excluding pension risk transfers rose 4%. Net investment income rose 16% to $6.1 billion, though adjusted net investment income grew a more moderate 6%. Asia was the standout segment, with adjusted earnings up 77% and sales up 34% on a constant currency basis, driven by Japan's new retirement-oriented products. Latin America adjusted earnings fell 33% on a Mexican value-added tax charge of $71 million after tax, although excluding notable items they rose 2%. RIS adjusted earnings declined 8% on a tough prior-year comparison, but ex-notables they grew 15%. The quarter also included an $89 million favorable annual actuarial assumption review. Capital and balance-sheet positioning remain solid. Book value per share rose 1% to $39.52 and adjusted book value per share rose 3% to $56.57. MetLife returned about $875 million to shareholders in the quarter through buybacks and dividends, and holding company cash and liquid assets were $4.9 billion. Management also highlighted $12 billion of pension risk transfer mandates secured in 4Q25 to date. Investors should weigh the strong underlying adjusted earnings momentum against the GAAP earnings decline, which is driven largely by market-sensitive derivative and investment items that management excludes from its adjusted measures.

Nov 5, 2025 8-K

METLIFE INC 8-K Report, Bylaw Amendment (Oct 14, 2025)

MetLife Inc. (MET) has filed a Current Report (8-K) detailing the elimination of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G. This action, effective October 14, 2025, follows the complete redemption, repurchase, or reacquisition of all outstanding shares of this preferred stock. The filing with the Delaware Secretary of State formally removes the Series G Preferred Stock provisions from MetLife's Amended and Restated Certificate of Incorporation. From an investor's perspective, this filing indicates a simplification of MetLife's capital structure. The elimination of this specific series of preferred stock suggests the company has managed its outstanding liabilities and financial obligations effectively. While this event does not involve new financial performance metrics or strategic shifts, it represents a housekeeping item that tidies up the company's corporate governance and share structure, potentially reducing administrative complexity.

Oct 14, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Sep 22, 2025)

MetLife, Inc. (MET) has filed a Form 8-K to provide investors with preliminary insights into its estimated variable investment income for the quarter ending September 30, 2025. The company anticipates that this income will meet its quarterly target of $425 million (pre-tax). This figure is part of MetLife's full-year guidance of approximately $1.7 billion (pre-tax) for variable investment income, which includes returns from private equity, real estate, other funds, and prepayment fees. It is crucial for investors to understand that this information is preliminary, unaudited, and based on data available as of the filing date. MetLife has not completed its financial closing procedures for the quarter, and actual results may differ materially. Investors should exercise caution and avoid drawing conclusions about other financial or operating data not provided in this disclosure. This preliminary data should not be considered a substitute for the comprehensive financial statements prepared under U.S. GAAP or indicative of future performance.

Sep 22, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (Sep 15, 2025)

MetLife, Inc. (NYSE: MET) disclosed in an 8-K filed September 15, 2025 that it received notice of an unsolicited "mini-tender" offer from Potemkin Limited to buy up to 10,000 shares of MetLife common stock at $53.00 per share. That price is roughly 34.42% below the $80.82 closing price on September 12, 2025. The offer covers about 0.00002% of shares outstanding as of August 31, 2025, so its direct financial impact on MetLife is negligible. MetLife does not endorse the offer, is not associated with Potemkin, and recommends that shareholders not tender their shares. It issued a news release (Exhibit 99.1) urging holders to check current market quotations, consult their broker or financial advisor, and take no action unless they have already tendered. Shareholders who already tendered may withdraw before the offer expires at 5:00 p.m. Eastern on Tuesday, October 7, 2025. For investors, this is a routine, non-material event. It is primarily a shareholder-protection communication and does not indicate any change in MetLife's operations, financial condition, capital structure, or strategy. The main risk is to individual shareholders who might tender at a deep discount, not to the company or to the broader investor base.

Sep 15, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (Sep 2, 2025)

MetLife, Inc. (NYSE: MET) disclosed in an 8-K filed September 2, 2025 that it will fully redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, on September 15, 2025, at a redemption price of $1,000 per share (the stated liquidation preference). The filing is a routine capital management event rather than an earnings or operational update, and it contains no financial results, guidance, or changes to business strategy. The semi-annual dividend of $19.250 per share will be paid separately on September 15, 2025, to holders of record as of August 29, 2025, and is not part of the redemption price. Dividends cease to accrue on and after the redemption date. Holders are not receiving any premium over liquidation preference, so the redemption is economically neutral to them beyond the final coupon and the loss of the ongoing high-yield income stream. For investors, the key takeaway is that MetLife is retiring a relatively high-coupon preferred security, which reduces its outstanding preferred capital and future preferred dividend obligations. The filing does not state the funding source or the reason for the redemption, so any read-through on capital planning should be drawn from MetLife's other disclosures. The notice is informational and does not itself constitute a formal notice of redemption under the preferred stock terms.

Sep 2, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (Aug 15, 2025)

MetLife, Inc. (NYSE: MET) filed an 8-K on August 15, 2025, under Item 8.01 (Other Events) to disclose its declaration of third-quarter 2025 preferred stock dividends across five series. The filing contains no financial results, guidance, or material corporate actions. The news release is attached as Exhibit 99.1. The declared dividends cover the floating rate Series A (quarterly, $0.35263005 per share), the 5.875% fixed-to-floating Series D (semi-annual, $29.375 per share), the 5.625% Series E (quarterly, $0.3515625 per depositary share), the 4.75% Series F (quarterly, $0.296875 per depositary share), and the 3.850% fixed rate reset Series G (semi-annual, $19.250 per share). All dividends are payable September 15, 2025, to holders of record as of August 29, 2025. The record date falls on August 29 because the nominal date of August 31 is a Sunday. For investors, this is a routine capital-management disclosure. It confirms that MetLife continues to meet its scheduled preferred obligations and that the preferred stock remains in place as part of its capital structure. Because these are non-cumulative preferreds, a future decision to skip a payment would not accrue arrears, so the declaration reflects board discretion rather than a guaranteed obligation.

Aug 15, 2025 10-Q

METLIFE INC Quarterly Report for Q2 Ended Jun 30, 2025

MetLife, Inc. (MET) reported its financial results for the period ending June 30, 2025. The company experienced a decrease in net income available to common shareholders to $698 million for the three months ended June 30, 2025, down from $912 million in the same period last year. Adjusted earnings available to common shareholders also saw a decline, coming in at $1.36 billion for the quarter, compared to $1.63 billion in the prior year's second quarter. This decrease was primarily driven by market factors, including higher interest credited expenses and lower variable investment income, as well as unfavorable underwriting and other insurance adjustments across several segments, particularly Group Benefits and Asia. Despite the decline in profitability, MetLife's total assets grew to $702.47 billion as of June 30, 2025, up from $677.46 billion at the end of 2024. The company continued its share repurchase program, acquiring approximately $1.92 billion in common stock during the first six months of 2025. MetLife also remains active in managing its capital, with significant repurchase authorizations in place. The company has also announced a pending acquisition of PineBridge Investments, expected to close by the end of 2025, which aims to bolster its investment management capabilities.

Aug 7, 2025 8-K

METLIFE INC 8-K Report, Financial Results (Aug 6, 2025)

MetLife's 2Q25 results (reported August 6, 2025) show a mixed quarter: the headline GAAP net income fell 23% to $698 million ($1.03 per share), while adjusted earnings, the company's preferred measure of underlying performance, declined 16% to $1.36 billion ($2.02 per share). The main drags were less favorable underwriting in Group Benefits, lower recurring interest margins in RIS, and sharply lower variable investment income, which fell to $195 million on weaker private equity returns. Net derivative losses of $796 million, driven by stronger equity markets and higher long-term rates, were the largest contributor to the GAAP decline. Adjusted premiums, fees and other revenues excluding pension risk transfers (PRT) grew 5% to $12.4 billion, and most segments other than MetLife Holdings showed growth. The quarter also showed underlying strength in several franchises. EMEA adjusted earnings rose 30% on volume growth, Latin America's constant-currency adjusted earnings rose 15%, and Asia sales increased 9% on a constant-currency basis, led by Japan and Korea. Book value per share rose 7% to $35.79 and adjusted book value per share rose 6% to $56.23. MetLife returned roughly $900 million to shareholders in the quarter through buybacks and dividends, and holding company cash and liquid assets stood at $5.2 billion. Management also reiterated progress on the Chariot Re, Talcott Financial Group and PineBridge Investments transactions, which it says are meant to accelerate growth in asset management and the retirement platform. For investors, the key questions are whether the decline in variable investment income and Group Benefits underwriting is cyclical or structural, and how quickly the announced strategic transactions can add earnings. The filing also shows that the Q2 direct expense ratio of 11.7% (excluding PRT and notable items) was below MetLife's 12.1% annual target, and that no notable items were recorded this quarter. The 8-K furnishes these materials rather than filing them, and the detailed results will be discussed on the August 7, 2025 earnings call.

Aug 6, 2025 8-K

METLIFE INC 8-K Report, Executive Changes (Jul 30, 2025)

MetLife (NYSE: MET) announced on July 30, 2025 that it has appointed Adrienne O'Neill as Executive Vice President and Chief Accounting Officer, effective September 2, 2025. O'Neill, 44, currently serves as Chief Financial Officer of the Asia Segment at Manulife Financial Corporation, and previously held Manulife's Global Controller and Group Chief Accounting Officer role and its Global Head of Investor Relations role. She will report to CFO John McCallion and will lead corporate accounting, reporting, and financial planning and analysis. The filing is primarily a personnel and compensation disclosure rather than a financial update. O'Neill's base salary is $525,000, with discretionary annual incentive eligibility under MetLife's existing plans (2025 awards pro-rated). She will also receive sign-on cash payments and sign-on equity awards with an aggregate grant-date value of $1,950,000, intended to offset compensation forfeited from Manulife. The filing states there is no arrangement under which she was selected and no family relationships with current directors or executive officers. For investors, the appointment fills a role held on an interim basis since March 2025 by Toby Srihiran Brown, who will return to his full-time role as EVP and Global Head of Reinsurance. The move signals a permanent finance leadership addition during the execution of MetLife's "New Frontier" strategy, though the filing contains no financial results or guidance changes.

Jul 30, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Jul 1, 2025)

MetLife, Inc. (NYSE: MET) disclosed on July 1, 2025 (furnished under Item 7.01, not filed) that its subsidiary completed the initial reinsurance transaction with Chariot Reinsurance, Ltd. (Chariot Re), a newly launched Bermuda-based Class E life and annuity reinsurer. Chariot Re will reinsure approximately $10 billion of liabilities, including structured settlement annuity contracts and group annuity contracts associated with pension risk transfers originated by MetLife. The transaction is structured as a strategic partnership rather than a simple sale of liabilities. Chariot Re is co-sponsored by MetLife and General Atlantic, with Chubb as lead investor. MetLife Investment Management and General Atlantic serve as its exclusive external asset managers, and Cynthia Smith, a former leader of MetLife's Group Benefits Regional Business, is CEO. MetLife states that its commitment to policyholders is unchanged and that it will continue to handle all customer-related functions. For investors, the key points are the capital and risk-transfer implications of ceding roughly $10 billion of liabilities, MetLife's ongoing economic interest as co-sponsor, and the fee and asset-management revenue opportunity for MetLife Investment Management within the New Frontier strategy. The filing does not disclose financial terms such as consideration, capital impact, or expected earnings effects, so those details would need to come from future MetLife disclosures.

Jul 1, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Jun 23, 2025)

MetLife Inc. (MET) has filed a Form 8-K to provide a preliminary, unaudited estimate of its variable investment income for the quarter ending June 30, 2025. The company anticipates variable investment income to be in the range of $175 million to $225 million (pre-tax). This disclosure is intended to offer early insight into a specific component of their expected financial performance ahead of the official earnings release and quarterly financial supplement scheduled for August 6, 2025. Investors should note that this information is preliminary and has not undergone the full financial closing procedures. Consequently, actual results could differ materially from these estimates. This disclosure is furnished under Regulation FD and is not intended to be a substitute for the comprehensive financial statements that will be filed later in accordance with U.S. GAAP, nor should it be used to infer other financial or operating data. Investors are advised to exercise caution when relying on this preliminary data.

Jun 23, 2025 8-K

METLIFE INC 8-K Report, Shareholder Vote Results (Jun 20, 2025)

MetLife, Inc. (MET) has filed an 8-K report detailing the outcomes of its annual meeting of common shareholders held on June 17, 2025. The key resolutions passed include the election of eleven directors for terms expiring at the 2026 annual meeting, the ratification of Deloitte & Touche LLP as the company's independent auditor for 2025, and an advisory approval of the compensation for Named Executive Officers. All director nominees received a substantial majority of "For" votes, indicating strong shareholder confidence in the current board. The ratification of the auditor and the advisory vote on executive compensation also saw significant shareholder approval, with "For" votes outnumbering "Against" votes by a wide margin in both cases. These results suggest a stable governance framework and continued shareholder support for the company's leadership and its chosen auditors. The "Broker Non-Votes" noted in the director elections represent shares held by brokers where the beneficial owner did not provide voting instructions. While these do not count for or against a proposal, their presence is standard in many shareholder meetings and does not appear to have impacted the decisive outcomes for the director elections or other proposals. Investors can view these outcomes as a positive sign of established corporate governance practices at MetLife.

Jun 20, 2025 8-K

METLIFE INC 8-K Report, Financial Obligation (Jun 17, 2025)

MetLife Inc. (MET) has announced the issuance of ¥87.84 billion (approximately $790 million USD as of June 2025, based on typical exchange rates) in yen-denominated senior notes through a private placement. This offering consists of six tranches with varying maturities ranging from 2032 to 2055 and coupon rates between 2.14% and 3.62%. The proceeds are earmarked for refinancing existing debt, specifically ¥25.2 billion of senior notes maturing in 2026, and for general corporate purposes. This transaction diversifies MetLife's funding sources and potentially extends its debt maturity profile. The issuance in a foreign currency indicates a strategic move to manage currency exposures or access international capital markets. While the notes are not registered under the Securities Act, they were offered in reliance on an exemption for private placements, a common practice for large corporate debt issuances. Investors should note that these are senior unsecured obligations of MetLife, Inc.

Jun 17, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (May 15, 2025)

MetLife, Inc. (NYSE: MET) filed an 8-K on May 15, 2025, under Item 8.01 (Other Events) to disclose that its board declared quarterly dividends on three series of non-cumulative preferred stock for the second quarter of 2025. The filing is routine in nature and contains no financial results, guidance, or material operational changes. The dividends cover the floating rate Series A (NYSE: MET PRA, $0.35141735 per share), the 5.625% Series E (NYSE: MET PRE, $0.3515625 per depositary share), and the 4.75% Series F (NYSE: MET PRF, $0.296875 per depositary share). Each Series E and Series F depositary share represents a 1/1,000th interest in a $25,000 liquidation preference preferred share. The dividends are payable June 16, 2025, to holders of record as of May 30, 2025. Because the scheduled record dates fell on a Saturday and Sunday, the company set the record date to the preceding business day. Investors who hold these preferred securities should note the May 30 record date to be entitled to the payment. Because the preferred stock is non-cumulative, a skipped dividend would not accumulate and be owed later, so the board's declaration is a meaningful signal of continued capital-return commitment. For common shareholders and bondholders, this filing has limited direct impact. It reflects ongoing capital management and maintenance of MetLife's preferred stock program, which helps support the company's capital position. The filing does not provide information on earnings, balance sheet changes, or strategic initiatives, so investors seeking performance insight should consult MetLife's quarterly earnings releases and periodic SEC reports.

May 15, 2025 10-Q

METLIFE INC Quarterly Report for Q1 Ended Mar 31, 2025

MetLife, Inc. (MET) reported a solid first quarter for 2025, with net income attributable to common shareholders of $879 million, an increase from $800 million in the prior year's first quarter. Adjusted earnings available to common shareholders remained stable at $1.3 billion year-over-year, demonstrating resilience in its core operations despite some market headwinds. Total revenues saw a significant increase to $18.6 billion, driven primarily by a substantial rise in premiums and a favorable shift in net derivative gains (losses), which more than offset a decrease in net investment income. The company continues to execute its strategic initiatives, including the pending acquisition of PineBridge Investments, which is expected to close in the second half of 2025, bolstering its asset management capabilities. Total assets grew to $677.5 billion from $688.3 billion, reflecting a solid investment portfolio. Total liabilities also increased, but equity remained relatively stable. The company's robust capital position, supported by strong adjusted earnings and careful liquidity management, positions it well to navigate the evolving economic landscape and pursue strategic growth opportunities. Investors should note the significant favorable change in net derivative gains, which significantly boosted net income, highlighting the impact of market volatility on reported earnings.

May 1, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Apr 30, 2025)

On April 30, 2025, MetLife (NYSE: MET) announced an agreement with Talcott Resolution Life Insurance Company, a subsidiary of Talcott Financial Group, to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves. The transaction is expected to generate roughly $250 million in combined value, comprising a ceding commission and capital released over time. MetLife positions the deal as a risk-transfer tool that reduces enterprise capital-markets risk, cuts variable annuity tail risk by lowering account values by about 40%, and accelerates the run-off of MetLife Holdings, the closed-block legacy businesses of its former U.S. Retail segment. The economic trade-off is explicit. MetLife expects roughly $100 million of foregone annual adjusted earnings, partly offset by about $45 million of annual hedge cost savings, for a net reduction of roughly $55 million per year in adjusted earnings. The deal is structured as modified coinsurance and funds withheld, and it is expected to close in the second half of 2025, subject to customary conditions and regulatory approvals. MetLife will retain responsibility for all customer-related functions. MetLife Investment Management also secured mandates to manage about $6 billion of assets for Talcott. Management framed the transaction as consistent with its New Frontier strategic priorities and disciplined risk management. Investors will likely focus on whether the reduced hedging and tail risk translate into lower earnings volatility and capital requirements, and on the trade-off between the lost earnings and the one-time value realized. The announcement was paired with a May 1, 2025 call to discuss first-quarter 2025 results and address questions about the agreement.

Apr 30, 2025 8-K

METLIFE INC 8-K Report, Financial Results (Apr 30, 2025)

MetLife reported first-quarter 2025 results that were mixed on the headline but solid on the underlying business. GAAP net income rose 10% to $879 million ($1.28 per share, up 16%), helped mainly by a swing to net derivative gains of $432 million from net derivative losses a year earlier. Adjusted earnings, the measure management uses to evaluate segment performance, rose only 1% to $1.35 billion, or $1.96 per diluted share (up 7%). Adjusted earnings were held back by unfavorable foreign currency effects, lower recurring interest margins, and weaker Asia results, partly offset by Group Benefits (up 29%) and higher variable investment income (up 26% to $327 million). Premiums, fees and other revenues rose 14% to $13.6 billion, but excluding pension risk transfers (PRT) growth was only 1%. Balance sheet and capital indicators were stable. Book value per share rose 2% to $35.16 and adjusted book value per share rose 4% to $55.01. MetLife returned $1.8 billion to shareholders in the quarter through buybacks and dividends, and the Board approved a new $3.0 billion repurchase authorization. Holding company cash and liquid assets were $4.5 billion, and the 2024 combined U.S. RBC ratio was 388%, above the 360% target. Strategically, MetLife agreed in April to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves to a subsidiary of Talcott Financial Group, a transaction expected to close in the second half of 2025 subject to regulatory approval. Management estimates the deal's total expected value at about $250 million, with foregone adjusted earnings of roughly $100 million a year partly offset by hedge cost savings of about $45 million a year. The company also cited a 2025 variable investment income target of about $1.7 billion pre-tax.

Apr 30, 2025 8-K

METLIFE INC 8-K Report, Executive Changes (Mar 28, 2025)

MetLife, Inc. (MET) has filed an 8-K report on March 27, 2025, primarily announcing the resignation of director David L. Herzog. Mr. Herzog will step down from the Board of Directors effective May 1, 2025, and will not seek re-election at the upcoming annual meeting. Importantly, the company has stated that Mr. Herzog's decision is not due to any disagreements regarding the Company's operations, policies, or practices. This event is considered routine and does not appear to signal any significant underlying issues with the company's governance or business operations at this time. Investors should monitor future board composition and any potential strategic implications arising from changes in board membership.

Mar 28, 2025 8-K

METLIFE INC 8-K Report, Financial Obligation (Mar 13, 2025)

MetLife Inc. (MET) has filed an 8-K report detailing the issuance of $1 billion in 6.350% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2055. This issuance was conducted under the company's existing shelf registration statement and a related prospectus supplement, with the transaction finalized on March 13, 2025. The purpose of this issuance is to raise capital, likely to bolster its financial flexibility and support its ongoing business operations. A significant event accompanying this debt issuance is the termination of the company's Replacement Capital Covenants. These covenants, originally established in connection with earlier debt issuances, were tied to specific "covered debt." The newly issued debentures now qualify as "covered debt," and the holders of these new debentures have consented to the termination of the prior covenants. This action simplifies MetLife's debt structure and removes past obligations associated with these covenants.

Mar 13, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (Mar 5, 2025)

MetLife, Inc. (NYSE: MET) filed this Form 8-K on March 5, 2025, under Item 8.01 (Other Events) to confirm its previously announced first quarter 2025 dividend of $0.35516415 per share on its floating rate non-cumulative preferred stock, Series A (NYSE: MET PRA), which has a $25 liquidation preference per share. The filing is a confirmatory announcement rather than a new capital action, and it does not change MetLife's financial results, guidance, or capital plans. Key dates for holders are as follows. The record date was February 28, 2025, which fell on a Sunday, March 2, 2025 in the release, and the dividend is payable March 17, 2025. As of the release, the NYSE had not yet set an ex-dividend date for the Series A preferred, and it was expected to do so following the confirmation. Investors should note that the record date and ex-dividend timing determine eligibility, so holders who wish to receive the payment should confirm the exchange's ex-dividend schedule. For investors, the filing is primarily administrative. It is relevant mainly to holders of the MET PRA preferred shares, and it reflects routine compliance with disclosure practices for a previously declared distribution. It contains no new material financial information about MetLife's operations, earnings, or balance sheet.

Mar 5, 2025 8-K

METLIFE INC 8-K Report, Financial Obligation (Mar 4, 2025)

MetLife Inc. (MET) has announced the completion of a private placement of $1.25 billion in Pre-Capitalized Trust Securities (P-Caps) maturing in 2055. These P-Caps serve as a contingent funding arrangement, providing MetLife with the right to issue up to $1.25 billion in 5.740% Senior Notes due 2055 to the Trust over a thirty-year period. The proceeds from the P-Cap issuance were invested by the Trust in U.S. Treasury securities, effectively securing the future obligation. This transaction establishes a forward-looking financing mechanism that strengthens MetLife's capital structure and provides a predetermined cost of capital for future debt issuance. While the P-Caps are restricted to qualified institutional buyers, the arrangement itself offers MetLife flexibility in managing its long-term liabilities and interest rate exposure. The company will pay a semi-annual facility fee on the unexercised portion of the Issuance Right, with specific triggers for automatic or mandatory exercise of the Senior Notes issuance.

Mar 4, 2025 8-K

METLIFE INC 8-K Report, Executive Changes (Feb 27, 2025)

MetLife Inc. (MET) announced a change in its Chief Accounting Officer role and an expansion of its Board of Directors in a recent 8-K filing. Effective March 15, 2025, Toby Srihiran Brown will assume the interim Chief Accounting Officer (CAO) position, succeeding Tamara L. Schock who previously indicated her intent to resign. Mr. Brown brings extensive experience within MetLife, having held various senior finance and operational roles, including his current position as Executive Vice President and Global Head of Reinsurance. This transition is part of an ongoing search for a permanent CAO. Furthermore, the Board of Directors has been expanded to fourteen members with the appointment of Christian Mumenthaler, effective May 1, 2025. Mr. Mumenthaler, who has been deemed an independent director, will serve on the Finance and Risk Committee and the Investment Committee. He will be compensated under the standard non-management director compensation plan, which includes a combination of stock and cash.

Feb 27, 2025 10-K

METLIFE INC Annual Report, Year Ended Dec 31, 2024

MetLife (MET) reported a stronger 2024 versus 2023, with net income available to common shareholders of $4.2 billion (diluted EPS $5.94) compared with $1.4 billion a year earlier, driven mainly by favorable investment gains/losses, derivative results and market risk benefit remeasurement. Adjusted earnings available to common shareholders, the company's preferred management measure, rose to $5.8 billion from $5.5 billion, with Asia (up $339 million on a reported basis) and Group Benefits and RIS as the largest contributors. Total revenues increased to $71.0 billion from $66.9 billion, supported by higher net investment income ($21.3 billion) and premium growth in Group Benefits and Latin America. Management set higher medium-term targets under its New Frontier five-year strategy, raising the adjusted return on equity target to 15%-17% (from 13%-15%), targeting double-digit adjusted EPS growth in the near term, and lowering the direct expense ratio target. The company returned about $21 billion to shareholders from 2020 through 2024, repurchased $3.2 billion of stock in 2024, and expects roughly $25 billion of free cash flow over the next five years. Holding company liquid assets were $5.1 billion, above the stated $3.0-$4.0 billion target. Key risks include exposure to interest rate movements (the 10-year Treasury sensitivity table shows material swings in adjusted earnings), elevated Level 3 fair value assets, long-term care and variable annuity guarantee liabilities, asbestos-related litigation, a pending Malaysia sale that was called off, the pending PineBridge acquisition, and a sizable regulatory and litigation backdrop including the New York False Claims Act suit. Statutory capital remains well above regulatory thresholds, with the Statement-Based Combined RBC ratio above 360%.

Feb 21, 2025 8-K

METLIFE INC 8-K Report, Corporate Update (Feb 18, 2025)

On February 18, 2025, MetLife, Inc. (NYSE: MET) declared dividends on five series of its preferred stock, totaling the first-quarter 2025 preferred dividend cycle. The declarations cover the 5.875% fixed-to-floating Series D (semi-annual, $29.375 per $1,000 share), the 5.625% Series E (quarterly, $351.5625 per $25,000 share, or $0.3515625 per depositary share), the 4.75% Series F (quarterly, $296.875 per $25,000 share, or $0.296875 per depositary share), the 3.850% fixed-rate reset Series G (semi-annual, $19.250 per $1,000 share), and the floating-rate Series A (quarterly, $0.35516415 per $25 share). The Series A dividend is subject to final confirmation that MetLife has met the financial tests in its certificate of designations, which the company expects to announce on or about March 5, 2025. The dividends are payable March 17, 2025, to holders of record as of February 28, 2025. The Series A record date falls on Sunday, March 2, 2025, so Series A holders of record on that date receive the payment. The New York Stock Exchange has not yet set an ex-dividend date for Series A and will do so after the confirmatory announcement. This is a routine capital-management disclosure rather than a material financial event. It does not report earnings, guidance, or changes to MetLife's financial condition. For income-focused preferred holders, it confirms the scheduled payouts and the timing of the Series A conditional payment. Because the preferred stock is non-cumulative, any future dividend the board does not declare would not accrue or be owed later.

Feb 18, 2025 8-K

METLIFE INC 8-K Report, Financial Results (Feb 5, 2025)

MetLife reported a solid close to 2024, with full-year adjusted earnings of $5.8 billion ($8.15 per share, up 12%) and adjusted earnings excluding total notable items of $5.77 billion ($8.11 per share, up 11%). Fourth-quarter adjusted earnings were $1.5 billion ($2.09 per share), and GAAP net income for the year rose to $4.2 billion ($5.94 per share) from $1.4 billion, helped by market risk benefit remeasurement gains and lower derivative and investment losses than in 2023. Growth was strongest in Asia (+26% for the year, +50% in Q4) and EMEA, while Group Benefits and RIS saw pressure in the quarter from lower non-medical health margins and recurring interest margins. Book value per share fell 4% to $34.28 because of unrealized investment losses, while adjusted book value rose 2% to $54.81. The key forward-looking news is the launch of the New Frontier five-year strategy and an upgraded outlook. Management raised its near-term adjusted return on equity target to 15%-17% from 13%-15%, set a new target of double-digit adjusted EPS growth, and lowered its direct expense ratio target to 12.1% near term and 11.3% over the New Frontier period. It also expects to generate roughly $25 billion of free cash flow over five years and to maintain its $3.0-$4.0 billion holding company cash target, with $5.1 billion currently held above that range. Capital and liquidity appear strong, with a U.S. RBC ratio above the 360% target and no material liquidity deficiencies expected. Investors should keep in mind that the outlook depends on assumptions about interest rates, a 5% S&P 500 return, and 9%-11% private equity returns. Variable investment income of $800 million for the year came in below the roughly $1.5 billion guidance, driven by weaker real estate returns, and the 2025 outlook for Group Benefits and RIS includes FX headwinds. The 8-K also notes that adjusted earnings in Q4 included net notable items of $10 million, primarily from a tax adjustment offset by a litigation charge.

Feb 5, 2025 8-K

METLIFE INC 8-K Report, Executive Changes (Jan 10, 2025)

MetLife Inc. (MET) announced the upcoming resignation of Tamara L. Schock, Executive Vice President and Chief Accounting Officer, effective on or about March 14, 2025. Ms. Schock's departure is attributed to personal reasons and is not a result of any disagreements with the company regarding its financial reporting, internal controls, operations, or policies. This change in a key financial leadership role may warrant investor attention as the company navigates its succession planning and ensures a smooth transition in its accounting oversight. While the report does not disclose any immediate financial impacts or strategic shifts stemming from this departure, investors should monitor future communications from MetLife for updates on the appointment of a successor and any potential effects on the company's financial reporting processes. The filing confirms that the resignation is not indicative of any underlying issues with the company's financial statements or internal controls.

Jan 10, 2025 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Dec 12, 2024)

MetLife's December 12, 2024 Form 8-K furnishes (not files) a news release and slide deck for its 2024 Investor Day, introducing the 'New Frontier' five-year strategy (2024-2029). The company commits to double-digit adjusted EPS growth (versus ~6% achieved over 2019-2024), a 15-17% adjusted return on equity (up from a 12-14% Next Horizon target), a 100-basis-point reduction in its direct expense ratio from 12.3%, and at least $25 billion of cumulative free cash flow from holding companies (versus ~$20 billion under Next Horizon). Management frames the plan around four growth priorities: extending leadership in Group Benefits, capitalizing on the U.S./Japan retirement platform, scaling asset management toward $1 trillion in AUM, and expanding in high-growth international markets such as Mexico, India, China and Brazil. For investors, the key message is that the targets are materially more ambitious on returns and cash generation, which the company supports with track-record evidence: 15.1% adjusted ROE year-to-date through Q3 2024 and Next Horizon targets beaten. The filing also points to capital-light growth levers, including a planned third-party capital 'sidecar' to expand liability origination, and a shrinking MetLife Holdings legacy block, which fell from 19% to 10% of enterprise adjusted earnings. The targets are forward-looking and dependent on interest rates, equity markets, and execution. Many figures are non-GAAP and adjusted, so investors should review the reconciliations and definitions in the exhibits. The filing contains no new financial results, guidance changes tied to a specific quarter, or reported losses. It is primarily a strategic and capital-markets update. Its significance lies in the multi-year targets it sets, which give investors measurable benchmarks against which to judge MetLife's 2024-2029 performance.

Dec 12, 2024 8-K

METLIFE INC 8-K Report, Regulation FD Disclosure (Dec 11, 2024)

MetLife (NYSE: MET) disclosed in this December 11, 2024 Form 8-K (Item 7.01, Regulation FD, with a news release furnished as Exhibit 99.1) that it, together with General Atlantic, is forming Chariot Reinsurance, Ltd. ("Chariot Re"), a to-be-registered Class E Bermuda-based life and annuity reinsurance company. MetLife has received conditional approval from the Bermuda Monetary Authority to register the entity, and Chariot Re is expected to launch in the first half of 2025, subject to regulatory approvals and other closing conditions. MetLife is targeting an initial cession of approximately $10 billion of statutory reserves tied to structured settlement and group annuity contracts associated with pension risk transfers, an amount subject to adjustment based on the final initial equity raised. The structure is a capital-light partnership. MetLife and General Atlantic each expect to hold roughly 15% of Chariot Re's equity, with an initial combined equity investment of over $1 billion. Chubb is expected to be an anchor third-party investor, and the remaining equity will be held by other third parties. MetLife expects the transaction could initially increase available capital by approximately $1 billion. MetLife Investment Management and General Atlantic would exclusively provide asset management to Chariot Re, while MetLife would retain all customer-related functions and its policyholder commitments would be unchanged. Bank of America is expected to provide financing. For investors, the key takeaways are the potential capital benefit (about $1 billion), the reinsurance of a sizable ~$10 billion block that can be adjusted, and the fee-generating asset management relationship. The filing is a forward-looking announcement; the transaction remains subject to regulatory approvals, closing conditions, and the final equity raise, so the timing and final size are not yet certain.

Dec 11, 2024